GammaTile

Stop the proliferation of residual tumor cells.
Placed at the time of tumor resection, GammaTile® implantable collagen tiles deliver immediate, targeted radiation, from inside the tumor cavity, for advanced local control.1-8

Why GammaTile?
Why

GammaTile?

More dose,
where you want it,
when you need it.9

GammaTile precisely delivers radiation directly to the resection cavity when the tumor burden is at its lowest, while minimizing exposure to healthy brain tissue.9

THE GAMMATILE ADVANTAGE

Bioresorbable,
conformable collagen tile
designed for precise, safe and effective internal radiation therapy.10

  • Each tile has four cesium-131 (Cs-131) seeds, with a half-life of 9.7 days.11,12
  • Seeds are offset 3mm from the surface of the tile to prevent very high dose radiation from coming in contact with adjacent brain tissue.11,12
  • Fixed source strength (3.5 U/seed) at implant reduces dosimetric variability across patients and may simplify studying outcomes.11

Controlled dose

Uniform radiation-source spacing helps give predictable, therapeutic radiation dose for advanced tumor control.11

SEE HOW GAMMATILE WORKS

The GammaTile difference
immediate, targeted, controlled
radiation therapy

In a retrospective dosimetric review of treatment options for recurrent brain metastasis, GammaTile is shown to deliver precise radiation directly to the resection cavity (RC), with minimal exposure to surrounding brain tissue.9

Axial illustration demonstrating the differences in biologically effective dose (BED) distribution amongst the radiation modalities

Images courtesy of Miami Cancer Institute.

BED10Gy90% Median

Results9

  • GammaTile delivers statistically significant higher BED at the RC than the other modalities (all p <0.05).
  • GammaTile’s BED was significantly lower 5mm away from the RC as compared to CyberKnife® (p = 0.045) and proton therapy (p = 0.03).
  • Dose metrics associated with radiation necrosis are significantly lower for GammaTile on pairwise comparisons (all p <0.05).
VIEW THE CLINICAL EVIDENCE

Brachytherapy reimagined

GammaTile’s innovative, tissue-sparing design addresses the challenges and limitations seen in traditional brain brachytherapy, such as the use of Iodine-125 and loose seed placement, particularly uneven dose distribution and exposure to healthy brain tissue.10

Faster

radiation delivery with shorter treatment duration.10

Increased

local control.1-8,10

Low rates

of radiation necrosis.1-8,10

EXPLORE CESIUM-131

Hear from
GammaTile
physicians

There’s currently no other device that’s able to achieve what GammaTile has for our brain tumor patients. It’s the first device of its kind, and its ability to deliver safe and effective surgically targeted radiation is groundbreaking in the neuro-oncology community.

Julian
Julian Bailes, MD
Julian Bailes, MD, System Physician Executive at Endeavor Health Neurosurgery, Bennett-Tarkington Chair of Neurosurgery at NorthShore Hospitals, and Clinical Professor of Neurosurgery at the University of Chicago Pritzker School of Medicine

GammaTile treatment for newly diagnosed brain tumors is a significant step forward for patients and an example of the benefits that focused neurosurgical research and clinical innovation can provide. The targeted radiation delivered by GammaTile will save lives and set the stage for further groundbreaking advances against brain tumors.

Vince Dinapoli, MD, PhD
Vince Dinapoli, MD, PhD
Neurosurgeon at Mayfield Brain and Spine, Director of the Brain Tumor Center at The Jewish Hospital – Mercy Health

With GammaTile, we can deliver radiation directly to the tumor site at the time of surgery without any delay. We are proud to provide such an innovative treatment option at Goodman Campbell Brain and Spine and be recognized as a GammaTile Center of Excellence. We are always looking for opportunities to give patients hope where options have been historically limited.

Charles G. Kulwin, MD
Charles G. Kulwin, MD
Neurosurgeon at Goodman Campbell Brain and Spine – Ascension St. Vincent

GammaTile modular structure allows for fast and accurate implantation after tumor resection, while providing a safe separation between the radioactive seeds and the brain tissue.

Clara Ferreira, PhD, DABR
Clara Ferreira, PhD, DABR
Associate Professor in the Department of Radiation Oncology, University of Minnesota Medical School-Twin Cities

The GammaTile Commitment Pledge
for recurrent brain tumors

If a GammaTile treatment of a recurrent brain tumor is canceled because intraoperative pathology reveals only necrotic tissue, we will update the invoice to reflect a $0 charge.*

CONTACT USORDER NOW
Connect with Us to learn more about integrating GammaTile into your treatment offerings.
* Per the GammaTile Commitment Product Policy, effective December 31, 2023. A purchase order must be submitted for the original order and the customer must not have any past due invoices with GT Medical Technologies. Additional Terms and Conditions apply. Please contact Customer Service for complete policy details.

REFERENCE: 1. Kutuk T, et al. Brachytherapy. 23(6):751-760 (2024). 2. Kutuk T, et al. Brachytherapy. 22(6):872-881 (2023). 3. Dharnipragada R, et al. Neurooncol Adv. 5(1):vdad062 (2023). 4. Imber BS, et al. J Neurooncol. 159(3):609-618 (2022). 5. Nakaji P, et al. Cureus. 12(11):e11570 (2020). 6. Yekula A, et al. J Neurooncol. 166(3):441-450 (2024). 7. Gessler DJ, et al. Neurooncol Adv. 4(1):1-11 (2022). 8. Smith N, et al. Neuro Oncol. 24(S6):S4-S15 (2022). 9. Brachman DG, et al. J Neurosurg. 131(6):1819-1828 (2018). 10. Kutuk T, et al. Brachytherapy and Radiation Principles in Clinical Practice. 48:795-820 (2024). 11. Garcia MA, et al. J Neurooncol. 166:203-212 (2024). 12. Gessler DJ, et al. Future Oncol. 16(30):2445-2455 (2020).
MKT-476-01